The Future of Biologics and Cell-Based Therapies in Neurological Disease

Prepared by Salience Clinical, LLC
Independent analysis at the intersection of clinical science, regulatory strategy, and market access

About Salience Clinical

Salience Clinical, LLC is a strategic advisory firm focused on clinical development strategy, regulatory alignment, medical affairs, and evidence generation for biotechnology, pharmaceutical, and medtech organizations.

The firm specializes in high-complexity therapeutic areas—including neurology, neurodegeneration, and rare disease—where scientific uncertainty, regulatory scrutiny, and reimbursement pressure converge.

This report reflects Salience Clinical’s independent perspective, informed by senior-level experience across development, regulatory engagement, and commercialization strategy.

Executive Summary

Cell-based therapies and advanced biologics are redefining what is possible in the treatment of neurological disease. Unlike traditional pharmacologic approaches, these modalities aim to directly influence disease biology through neuronal replacement, gene correction, immune modulation, or sustained protein expression.

What was once theoretical is now clinically tangible.

Recent progress includes:

• iPSC-derived neuronal transplantation demonstrating biological activity in Parkinson’s disease
• Disease-modifying antibody therapies in Alzheimer’s disease
• Transformative gene therapy outcomes in spinal muscular atrophy

Yet despite this momentum, widespread adoption remains constrained by a set of persistent challenges:

• Reliable delivery into the central nervous system
• Demonstration of clinically meaningful benefit in heterogeneous populations
• Scalable and reproducible manufacturing
• Management of immunogenicity and long-term safety
• Alignment of reimbursement models with high upfront costs

A critical enabler of progress is the emergence of blood-based biomarkers, which are improving patient selection, accelerating trial timelines, and enabling more precise therapeutic deployment.

From Salience Clinical’s perspective, success in this domain will require more than innovation it will require integration: aligning biology, manufacturing, regulation, and economics into a coherent development strategy.

Introduction: Beyond Conventional Pharmacology

Neurological diseases have historically resisted conventional therapeutic approaches. Small molecules and first-generation biologics have struggled against the unique constraints of the central nervous system, including:

• The blood–brain barrier
• Cellular and circuit-level complexity
• Limited intrinsic regenerative capacity
• Multifactorial disease biology

Cell-based therapies and advanced biologics represent a shift from symptom management to biological intervention. These modalities offer capabilities that traditional drugs cannot:

• Replacement of lost or dysfunctional neurons
• Localized, sustained delivery of therapeutic proteins
• Modulation of immune and inflammatory pathways
• Structural and functional support of neural circuits

The ambition is clear: not simply to slow disease progression, but to alter its trajectory.

Current Landscape of Cell-Based Therapies

Induced Pluripotent Stem Cells (iPSCs)

iPSC-derived dopaminergic neurons represent the most advanced neuronal replacement strategy in clinical development for Parkinson’s disease.

Programs across Japan, the United States, and Europe are evaluating implantation of dopaminergic progenitors into the putamen. Early clinical data particularly from work led by Kyoto University demonstrate:

• Sustained increases in dopamine uptake on PET imaging
• Evidence of cell survival and functional integration
• No signals of tumorigenesis or uncontrolled proliferation

While clinical efficacy remains under investigation, these findings establish biological proof-of-concept.

Key translational considerations include:

• Manufacturing consistency and lineage specification
• Use of HLA-matched allogeneic cell banks
• Long-term safety monitoring and durability of effect

Mesenchymal Stem Cells (MSCs)

MSCs operate primarily through paracrine signaling and immune modulation, rather than direct neuronal replacement.

Clinical programs in ALS and related disorders have shown:

• Favorable safety profiles
• Modest and variable efficacy signals

Emerging interest in MSC-derived extracellular vesicles reflects efforts to improve:

• Stability
• Scalability
• Manufacturing reproducibility

However, consistent clinical benefit remains to be demonstrated, reinforcing the need for precise patient selection and endpoint alignment.

Neural Progenitor Cells

Neural progenitor approaches are being explored across stroke, traumatic brain injury, and neurodegenerative disease.

Rather than reconstructing specific neural pathways, these therapies aim to:

• Enhance endogenous repair mechanisms
• Support functional recovery through host–environment interaction

Their success will depend on both biological activity and effective delivery strategies.

Biologics: Gene and Antibody-Based Therapies

AAV Gene Therapy

Parkinson’s Disease

Gene therapy approaches have targeted:

• Neurotransmitter synthesis pathways
• Neurotrophic support mechanisms

While early trials demonstrated biological activity, many failed to achieve clinical endpoints—highlighting challenges related to:

• Placebo effects
• Target engagement
• Disease heterogeneity

Second-generation programs now incorporate:

• Improved vector design
• MRI-guided delivery techniques

These advances reflect a growing recognition that delivery is as critical as mechanism.

Alzheimer’s Disease

Gene therapy strategies in Alzheimer’s focus on:

• Enhancing clearance of pathological proteins
• Supporting neuronal survival

However, the diffuse nature of the disease presents substantial barriers to effective and safe delivery. To date, these approaches remain investigational.

ALS and Spinal Muscular Atrophy

Gene therapy has demonstrated its most dramatic success in spinal muscular atrophy, where onasemnogene abeparvovec established a new therapeutic paradigm.

Efforts to extend this success into ALS highlight:

• The promise of genetically defined subpopulations
• The limitations of single-target approaches in complex diseases

Antibody-Based Biologics

The approvals of lecanemab and donanemab mark a turning point in Alzheimer’s disease treatment, establishing the first disease-modifying therapies.

These agents demonstrate:

• Statistically significant slowing of cognitive decline
• Proof that targeting underlying pathology can translate into clinical effect

At the same time, they underscore:

• Modest effect sizes
• The importance of early intervention
• The need for careful safety monitoring

Next-generation programs targeting tau, alpha-synuclein, and TDP-43 are refining approaches to:

• Epitope selection
• Brain penetration
• Dose optimization

Neuropsychiatric Applications

Biologics are increasingly being explored in neuropsychiatric disorders, particularly where immune dysregulation plays a role.

Emerging evidence suggests:

• Subsets of patients with inflammatory signatures may respond to immunomodulatory therapies
• Biomarker-defined stratification will be critical to success

This reinforces a broader shift toward precision medicine in psychiatry.

Diagnostic Transformation: Blood-Based Biomarkers

Blood-based biomarkers are reshaping both development and clinical care in neurodegenerative disease.

In Alzheimer’s disease, assays such as p-tau217 are approaching the diagnostic performance of PET imaging, enabling:

• Earlier detection
• More efficient clinical trial screening
• Real-time monitoring of therapeutic effect

These tools represent a foundational enabler of precision therapeutic deployment.

Manufacturing, Regulatory, and Safety Considerations

Advanced therapeutics introduce new layers of complexity:

• Manufacturing: Requires robust quality systems and reproducibility at scale
• Regulation: Demands early and continuous engagement with agencies
• Safety: Requires long-term monitoring, particularly for gene and cell therapies

Allogeneic approaches offer scalability but introduce immunological considerations.
Autologous approaches reduce immune risk but increase logistical complexity.

Success depends on integrating these factors early in development not addressing them retrospectively.

Economic and Market Realities

The economics of advanced therapies present a fundamental challenge:

• High upfront costs
• Uncertain long-term benefit
• Pressure from payers and health systems

Sustainable adoption will require:

• Strong health-economic evidence
• Innovative reimbursement models (e.g., outcomes-based payments)
• Clear demonstration of long-term value

Future Outlook

The trajectory of neurological therapeutics is clear but not guaranteed.

The next decade will reward organizations that can integrate:

• Biomarker-driven patient selection
• Scalable, regulator-ready manufacturing
• Clinically meaningful and measurable endpoints
• Commercial strategies aligned with payer expectations

The defining factor will not be technological innovation alone, but execution across the full development continuum.

Cell-based therapies and advanced biologics have moved from conceptual promise to clinical reality. Their ultimate impact, however, will depend on disciplined strategy rather than scientific ambition alone.

The future of neurology will not be shaped by isolated breakthroughs, but by coordinated progress across science, regulation, and healthcare delivery systems.